Full-Time
Posted on 2/18/2025
AI-driven healthcare data analysis platform
$110k - $160kAnnually
Senior
Company Historically Provides H1B Sponsorship
Chicago, IL, USA + 1 more
More locations: New York, NY, USA
This is a hybrid role, requiring some in-office presence.
You match the following Tempus's candidate preferences
Employers are more likely to interview you if you match these preferences:
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus also conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on personalized medicine, aiming to improve care and treatment options for patients.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$894.9M
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression
Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).
Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.
Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter's ArteraAI prostate test.
Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation.